Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Emory University
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Taofeek K. Owonikoko, Emory University
ClinicalTrials.gov Identifier:
NCT01270321
First received: January 4, 2011
Last updated: October 22, 2014
Last verified: October 2014

January 4, 2011
October 22, 2014
November 2010
October 2015   (final data collection date for primary outcome measure)
Response rate [(complete response (RR) + partial response (PR)] [ Time Frame: After every 2 cycles on therapy ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01270321 on ClinicalTrials.gov Archive Site
Progression-free survival [ Time Frame: After every 2 cycles of treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer
A 3-Arm Randomized Phase II Trial Evaluating Single Agent and Combined Efficacy of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer

The purpose of this study is to determine the effectiveness of two anticancer drugs, everolimus and pasireotide, in patients with thyroid cancer when the cancer is no longer responding to treatment with radioiodine or where it is deemed unsafe for the patient to receive additional radioiodine treatment. The investigators also want to establish the best manner of taking the two medications when used together to treat thyroid cancer. In particular, the investigators want to know if it is better to give both at the same time or add a second medication after the first one has stopped working.

This study will also look at specific substances called biomarkers in your blood, and in the tumor tissue which are involved in the growth of tumor cells, and determine if the levels of these biomarkers are related to your response to treatment or development of side effects.

Everolimus, also known by the brand name, Afinitor, is a biologic drug approved by the Food and Drug Administration (FDA) for the treatment of kidney cancer. It works by preventing cancer cells from multiplying and it also makes them more likely to die from the treatment.

Pasireotide also known by the name, SOM230 is a new medication that is not yet approved by the FDA for the treatment of cancer. It is a newer form of a drug called octreotide, which is approved for the treatment of cancer arising from endocrine organs. Pasireotide works by binding to a protein called somatostatin receptor, which is expressed in many tissues throughout the body including thyroid cancer cells. Pasireotide prevents the action of somatostatin by binding to these receptors.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Thyroid Cancer
  • Drug: Everolimus
    Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
    Other Name: Afinitor
  • Drug: Pasireotide
    Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide LAR 60mg i.m. once every 4 weeks
    Other Name: SOM230
  • Drug: Everolimus and Pasireotide
    Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide LAR 60mg i.m. once every 4 weeks
    Other Names:
    • Afinitor
    • SOM230
  • Experimental: Arm A (Everolimus alone)
    Everolimus alone followed by Everolimus + Pasireotide at the time of progression
    Intervention: Drug: Everolimus
  • Experimental: Arm B (Pasireotide alone)
    Pasireotide alone followed by Everolimus + Pasireotide at the time of progression
    Intervention: Drug: Pasireotide
  • Experimental: Arm C (Everolimus + Pasireotide)
    Intervention: Drug: Everolimus and Pasireotide
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
45
June 2016
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologic or cytologic confirmation of thyroid cancer (papillary, follicular, medullary); histologic variants such as Hurthle and tall cell variants are allowed.
  2. Biochemical or radiologic documentation of disease progression within the last 12 months prior to enrollment.
  3. Presence of at least one site of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.
  4. Patient must have radioiodine refractory disease as defined by one or more of the following conditions:

    • All cases of medullary thyroid carcinoma.
    • No iodine-uptake on a post- radioactive iodine treatment scan (in presence of low iodine diet and thyroid stimulating hormone (TSH) suppression) in an anatomically defined lesion that qualifies as target lesion by RECIST criteria.

    OR

    • If there is demonstrable iodine-uptake: the last radioiodine therapy of (≥ 100 mCi) was given within the last 16 months OR if given more than 16 months before enrollment, there is evidence of disease progression after each of the last two radioiodine treatment performed within 16 months of each other (each dose should be ≥ 100mCi).

    OR

    • If the patient has received the maximum cumulative life time dose of radioactive iodine treatments of at least 600 mCi.

  5. Age ≥ 18 years.
  6. Minimum of four weeks since any major surgery or since completion of radiation (patients should have adequately recovered from the acute toxicities of any prior therapy).
  7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
  8. Life expectancy of at least 6 months.
  9. Adequate bone marrow function as shown by: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, Hgb > 9 g/dL.
  10. Adequate liver function as shown by: serum bilirubin ≤ 1.5 x upper limit of normal (ULN), and serum transaminases activity ≤ 3 x ULN, with the exception of serum transaminases (< 5 x ULN) if the patient has liver metastases.
  11. Adequate renal function as shown by serum creatinine ≤ 1.5 x ULN or glomerular filtration rate (GFR) of 60cc/ml using the formula of Cockroft and Gault.
  12. Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.
  13. Women of childbearing potential must have a negative serum pregnancy test within 14 days of the administration of the first study treatment. Women must not be lactating. Both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the study.
  14. Signed informed consent to participate in the study must be obtained from patients after they have been fully informed of the nature and potential risks by the investigator (or his/her designee) with the aid of written information.
  15. International normalized ratio (INR) and prothrombin time (PTT) ≤1.5 x ULN. (Anticoagulation is allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for >2 weeks at time of randomization.)

Exclusion Criteria:

  1. Prior treatment with not more than 1 systemic agent.
  2. Patients who have undergone major surgery within 4 weeks prior to study enrollment (tracheotomy, feeding tube or vascular access catheter placement and interventional procedures such as bronchoscopy, upper GI endoscopy or colonoscopy are not considered major surgery).
  3. Chronic treatment with systemic steroids or another immunosuppressive agent.
  4. Patients should not receive immunization with attenuated live vaccines during study period or within 1 week of study entry.
  5. Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases.
  6. Patients with prior or concurrent malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, or other adequately treated in situ cancer, or any other cancer from which the patient has been disease free for five years.
  7. Patients with uncontrolled diabetes mellitus or a fasting plasma glucose > 1.5 ULN. Note: At the principle investigator's discretion, non-eligible patients can be re-screened after adequate medical therapy has been instituted.
  8. Patients with symptomatic cholelithiasis (asymptomatic gall stone discovered on screening US should be reviewed by the PI but will not lead to automatic exclusion).
  9. Liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class C):

    • History of liver disease, such as cirrhosis or chronic active hepatitis B and C.
    • Presence of Hepatitis B surface antigen (HbsAg).
    • Presence of Hepatitis C antibody test (anti-HCV).
  10. Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment.
  11. QT related exclusion criteria:

    • QT corrected Fridericia's method (QTcF) at screening > 470 msec.
    • History of syncope or family history of idiopathic sudden death.
    • Sustained or clinically significant cardiac arrhythmias.
    • Risk factors for Torsades de Pointes such as hypokalemia, hypomagnesemia, cardiac failure, clinically significant/symptomatic bradycardia, or high-grade atrioventricular (AV) block.
    • Concomitant disease(s) that could prolong QT such as autonomic neuropathy (caused by diabetes, or Parkinson's disease), HIV, cirrhosis, uncontrolled hypothyroidism or cardiac failure.
    • Concomitant medication(s) known to increase the QT interval.
  12. Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunocompromise, including a positive HIV test result (ELISA and Western blot).
  13. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    • Severely impaired lung function (as defined as spirometry and diffusing capacity of lung for carbon monoxide [DLCO] that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air).
    • Any active (acute or chronic) or uncontrolled infection/ disorders.
    • Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy.
    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001.
    • Patients who have a history of alcohol or drug abuse in the 6 month period prior to receiving treatment with pasireotide or RAD001.
    • History of, or current alcohol misuse/abuse within the past 12 months.
    • Acute or chronic pancreatitis.
  14. Women who are pregnant or breast feeding, or women/men of reproductive potential who are not using and unwilling to practice an effective method of birth control. (Women of childbearing potential [WOCBP] must have a negative serum pregnancy test within 7 days prior to administration of pasireotide and RAD001.)
  15. Male patient whose sexual partner(s) are WOCBP who are not willing to use adequate contraception, during the study and for 8 weeks after the end of treatment.
  16. Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients.
  17. Known hypersensitivity to somatostatin analogues or any component of the pasireotide or octreotide LAR formulations.
  18. History of noncompliance to medical regimens.
  19. Patients unwilling to or unable to comply with the protocol.
  20. Patients taking medications known to be strong cytochrome P450, family 3, subfamily A (CYP3A) inhibitors.
Both
18 Years and older
No
Contact: Taofeek Owonikoko, MD, PhD 404-778-4383 towonik@emory.edu
United States
 
NCT01270321
IRB00041909, WCI1777-09
Yes
Taofeek K. Owonikoko, Emory University
Emory University
Novartis
Principal Investigator: Taofeek Owonikoko, MD, PhD Emory University Winship Cancer Institute
Emory University
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP